Pharmaceutical Business review -

Pharmaceutical Business review -

Pharmaceutical Business review is using cookies

Continue Learn More

Close

April 16, 2021

GSK and Vir announce EMA review of VIR-7831 for early treatment of Covid-19

GlaxoSmithKline and Vir Biotechnology have announced the European Medicines Agency (EMA) review of VIR-7831 (GSK4182136) for the early treatment of Covid-19.

Ahead of any formal Marketing Authorisation Application (MAA), the review will assist in EU-wide recommendations for countries that may take evidence-based decisions on the premature use of the medicine.Credit: Mohamed Hassan/Pixabay.

March 10, 2021

Japan’s Takeda to acquire the US’ Maverick Therapeutics

Oncology

Japan-based Takeda Pharmaceutical Company Limited has entered into an agreement to acquire private biopharmaceutical company Maverick Therapeutics, Inc. in a bid to expand its novel immuno-oncology portfolio. Credit: National Cancer Institute/Unsplash

February 9, 2021

USFDA awards Breakthrough Therapy designation to Novartis’ asciminib

Approvals

Medicines that are being assessed for critical conditions are granted BTD if early clinical evidence indicates significant improvement potential over available therapy. Credit: Vachagan Malkhasyan from Pixabay

Contracts

March 17, 2021

AstraZeneca to deliver 500,000 more doses of AZD7442 to US

AstraZeneca’s long-acting antibody (LAAB) combination AZD7442 is in the late-stage development for the prevention and treatment of the Covid-19 virus. Credit: Steven Cornfield/Unsplash.

Enveric Biosciences signs licensing agreement with Diverse Biotech

Ocugen signs agreement with Bharat Biotech to distribute Covid-19 vaccine in the US

Lilly to provide antibody therapies at Indiana hospitals for treating COVID-19

Deals

Deals April 14, 2021

Dr. Reddy’s secures EUA for Sputnik V in India

Pharmaceutical Business Review

Sanofi acquires Tidal Therapeutics

Piramal to acquire APIs manufacturer Hemmo Pharmaceuticals

Takeda Pharmaceutical concludes sale of OTC and non-core assets to Orifarm for $670m

Drug Manufacturing

Popular

PRESS RELEASES

Novo Nordisk Pharmatech’s New CEO Has a Head Start

Gerresheimer Participates in the European Joint Project Furnace for the Future (F4F)

Strategikon Pharma Announces New Software Release of Clinical Maestro

Gerresheimer with Positive Start to the Financial Year 2021

Virtual Pharma Training Including New Digital eLearning

Suppliers

Whitepapers

SnAP Reagents

Diazirines for Photoaffinity Labelling

Sulfoximines for Drug Design